AP-2gamma promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene

Related Experiment Video

Updated: Jun 19, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Christopher M J Williams1, Angelo G Scibetta, J Karsten Friedrich

  • 1Barts & The London School of Medicine and Dentistry, Queen Mary University of London, Centre for Tumour Biology, Institute of Cancer, Charterhouse Square, London, UK.

The EMBO Journal
|October 3, 2009
PubMed

Insights

Overexpression of activator protein 2 gamma (AP-2gamma) in breast tumors predicts poor outcomes. Silencing AP-2gamma in breast cancer cells halts cell cycle progression and impacts gene expression, offering new therapeutic insights.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Overexpression of the activator protein (AP)-2gamma transcription factor is linked to poor prognosis and hormone therapy failure in breast tumors.
  • Understanding AP-2gamma's role is crucial for developing effective breast cancer treatments.

Purpose of the Study:

  • To investigate the function of AP-2gamma in breast carcinoma using RNA interference and gene expression profiling.
  • To elucidate the molecular mechanisms by which AP-2gamma influences breast cancer cell behavior.

Main Methods:

  • Utilized RNA interference to silence AP-2gamma in MCF-7 breast cancer cells.
  • Performed gene expression profiling, flow cytometry, reporter assays, and chromatin immunoprecipitation to analyze gene regulation and cell cycle effects.

Main Results:

  • AP-2gamma silencing resulted in cell cycle G1/S arrest and induced the cyclin-dependent kinase inhibitor p21cip/CDKN1A.
  • Demonstrated direct functional interaction of AP-2gamma at the CDKN1A promoter, leading to altered chromatin conformation and gene expression.
  • AP-2gamma overexpression promotes breast epithelial proliferation.

Conclusions:

  • AP-2gamma plays a significant role in breast cancer cell cycle progression and proliferation.
  • Loss of estrogenic regulation of AP-2gamma may contribute to hormone therapy resistance in breast cancer patients.

More Related Videos

Analysis of Cell Cycle Position in Mammalian Cells12:19

Analysis of Cell Cycle Position in Mammalian Cells

Published on: January 21, 2012

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...